News on infantile haemangioma. Part 1: clinical course and pathomechanism

H. De Leye; J. Saerens; S. R. Janmohamed

doi:10.1111/ced.14502

News on infantile haemangioma. Part 1: clinical course and pathomechanism

H. De Leye, J. Saerens, S. R. Janmohamed

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Currently, there is no doubt that the first choice of treatment for alarming infantile haemangiomas (IHs) is oral beta-blockers. However, research in this field remains active, as the pathogenesis of IH is still not completely elucidated. Furthermore, there are different approaches to the management of IHs with beta-blockers. In Part 1 of this review we will discuss the state-of-the-art evidence for IH with regard to (i) the definition, epidemiology, course, risk factors and sequelae, and (ii) the pathogenesis, focusing on genetic studies. This review will update the reader on the latest developments in the pathogenesis of IH. Furthermore, we hope this review will give more insight into risk factors and sequelae of IH, thereby contributing to better decisions in the clinical management of patients with IH. The therapy and evaluation of IHs will be discussed in Part 2 of this review.

Original language	English
Pages (from-to)	473-479
Number of pages	7
Journal	Clinical and Experimental Dermatology
Volume	46
Issue number	3
DOIs	https://doi.org/10.1111/ced.14502
Publication status	Published - Apr 2021

Bibliographical note

Funding Information:
SJ received unrestricted funding from Pierre Fabre Benelux. The other authors declare that they have no conflicts of interest.

Publisher Copyright:
© 2020 British Association of Dermatologists

Keywords

infantile haemangiomas

Access to Document

10.1111/ced.14502

Cite this

@article{eda8ed9d244b4a9f96fd1ea8abdd022e,

title = "News on infantile haemangioma. Part 1: clinical course and pathomechanism",

abstract = "Currently, there is no doubt that the first choice of treatment for alarming infantile haemangiomas (IHs) is oral beta-blockers. However, research in this field remains active, as the pathogenesis of IH is still not completely elucidated. Furthermore, there are different approaches to the management of IHs with beta-blockers. In Part 1 of this review we will discuss the state-of-the-art evidence for IH with regard to (i) the definition, epidemiology, course, risk factors and sequelae, and (ii) the pathogenesis, focusing on genetic studies. This review will update the reader on the latest developments in the pathogenesis of IH. Furthermore, we hope this review will give more insight into risk factors and sequelae of IH, thereby contributing to better decisions in the clinical management of patients with IH. The therapy and evaluation of IHs will be discussed in Part 2 of this review.",

keywords = "infantile haemangiomas",

author = "{De Leye}, H. and J. Saerens and Janmohamed, {S. R.}",

note = "Funding Information: SJ received unrestricted funding from Pierre Fabre Benelux. The other authors declare that they have no conflicts of interest. Publisher Copyright: {\textcopyright} 2020 British Association of Dermatologists",

year = "2021",

month = apr,

doi = "10.1111/ced.14502",

language = "English",

volume = "46",

pages = "473--479",

journal = "Clinical and Experimental Dermatology",

issn = "0307-6938",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - News on infantile haemangioma. Part 1

T2 - clinical course and pathomechanism

AU - De Leye, H.

AU - Saerens, J.

AU - Janmohamed, S. R.

N1 - Funding Information: SJ received unrestricted funding from Pierre Fabre Benelux. The other authors declare that they have no conflicts of interest. Publisher Copyright: © 2020 British Association of Dermatologists

PY - 2021/4

Y1 - 2021/4

N2 - Currently, there is no doubt that the first choice of treatment for alarming infantile haemangiomas (IHs) is oral beta-blockers. However, research in this field remains active, as the pathogenesis of IH is still not completely elucidated. Furthermore, there are different approaches to the management of IHs with beta-blockers. In Part 1 of this review we will discuss the state-of-the-art evidence for IH with regard to (i) the definition, epidemiology, course, risk factors and sequelae, and (ii) the pathogenesis, focusing on genetic studies. This review will update the reader on the latest developments in the pathogenesis of IH. Furthermore, we hope this review will give more insight into risk factors and sequelae of IH, thereby contributing to better decisions in the clinical management of patients with IH. The therapy and evaluation of IHs will be discussed in Part 2 of this review.

AB - Currently, there is no doubt that the first choice of treatment for alarming infantile haemangiomas (IHs) is oral beta-blockers. However, research in this field remains active, as the pathogenesis of IH is still not completely elucidated. Furthermore, there are different approaches to the management of IHs with beta-blockers. In Part 1 of this review we will discuss the state-of-the-art evidence for IH with regard to (i) the definition, epidemiology, course, risk factors and sequelae, and (ii) the pathogenesis, focusing on genetic studies. This review will update the reader on the latest developments in the pathogenesis of IH. Furthermore, we hope this review will give more insight into risk factors and sequelae of IH, thereby contributing to better decisions in the clinical management of patients with IH. The therapy and evaluation of IHs will be discussed in Part 2 of this review.

KW - infantile haemangiomas

UR - http://www.scopus.com/inward/record.url?scp=85097046124&partnerID=8YFLogxK

U2 - 10.1111/ced.14502

DO - 10.1111/ced.14502

M3 - Article

AN - SCOPUS:85097046124

SN - 0307-6938

VL - 46

SP - 473

EP - 479

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

IS - 3

ER -

News on infantile haemangioma. Part 1: clinical course and pathomechanism

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this